Our work in drug-resistant TB
The Union advocates for increased research and development, and conducts clinical trials to reduce treatment time and improve outcomes for patients in countries with the highest burdens of disease.
The Union also provides practical and experience-based support to countries implementing care for people with DR-TB. Our expertise is based on our extensive research with partners supporting the nine-month regimen, including partnering on the first randomised control trial into a new regimen for multidrug-resistant TB (TREAT TB).
With the new World Health Organization guidelines focusing on shorter, all oral, regimens for MDR-TB, The Union continues to support countries to implement the latest evidence-based treatments.
Read more about TREAT TB (Technology, Research, Education and Technical Assistance for Tuberculosis), an ambitious initiative that was launched by The Union, seeking to contribute new knowledge regarding shorter, more tolerable treatment regimens for MDR-TB.
The Union used an operational research approach to test a shortened treatment regimen for multidrug-resistant TB. The study first demonstrated a greater than 80% success rate in Bangladesh, Cameroon and Niger and The Union continued to work to develop and implement shorter more effective regimens for the treatment of MDR-TB.
DR-TB Union news
An Editorial in a forthcoming issue of IJTLD describes the rationale for launching IJTLD OPEN. The preprint is free to read.
Global reporting on TB in children and adolescents: how far have we come and what remains to be done?
An Editorial in a forthcoming issue of IJTLD Open highlights the need for further progress in tackling TB in children and adolescents. The preprint is free to read.
The second United Nations high-level meeting on the fight to end TB: action is needed to turn the tide by 2030
An Editorial in the September issue of PHA highlights the need to accelerate progress towards TB elimination.